Kodiak Sciences CEO and leadership

Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, he has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop novel medicines for highly prevalent diseases. Under Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates. Previously, Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Perlroth co-founded Avidia, a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.

Results driven finance executive with strategic, technical and leadership skills honed through over twenty years of experience in complex global organizations and early stage businesses. Expert at building and transforming financial functions to accelerate value creation.

Specialties: Strategic planning and analysis, business development, capital formation and structure, accounting and SEC reporting, financial planning and analysis, SOX 404, global taxation

Jason Ehrlich is a Chief Medical Ofcr/Chief Dev Ofcr at Kodiak Sciences Inc. He has worked as Global Head:Clinical Ophthalmology at Genentech. Jason works or has worked as Head:Clinician at Lucentis - Genentech. He attended Princeton University, Stanford University, and Board of Trustees of The Leland Stanford Junior University/The.

Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, he has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop novel medicines for highly prevalent diseases. Under Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates. Previously, Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Perlroth co-founded Avidia, a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.

Victor Perlroth co-founded Kodiak Sciences in 2009 and is the company’s Chairman and Chief Executive Officer. Together with a talented core team, he has built Kodiak on a foundation of scientific excellence with a simple mission—to design and develop novel medicines for highly prevalent diseases. Under Perlroth’s leadership, Kodiak is building a pipeline of potentially life transforming ophthalmology drug candidates. Previously, Perlroth served as Venture Partner and then Entrepreneur in Residence at MPM Capital, a dedicated healthcare venture capital investment firm. In 2003, Perlroth co-founded Avidia, a biopharmaceuticals drug discovery and development company where he served as General Manager and Vice President of Corporate Development. In this role, at various times he had broad management responsibility across both corporate and research and development activities. Perlroth was one of two principals involved in the acquisition of the company by Amgen for $450 million. Earlier, Perlroth worked at Guzik Technical Enterprises, the industry-leading provider of test equipment to the hard disk drive industry, where he was Chief Operating Officer. Perlroth earned his M.D. and M.B.A. degrees from Stanford University and an A.B. in Molecular Biology summa cum laude from Princeton University.